Revenue for the twelve months ended December 31, 2025, was $5.7 million, a decrease from $6.6 million for the same period in 2024. Gross profit for 2025 was $2.1 million, down from $2.6 million in 2024. Selling, general and administrative (SG&A) expenses significantly increased to $8.6 million in 2025 from $4.8 million in 2024, primarily due to professional fees for the initial public offering and becoming a public entity, as well as increased information technology support costs. Loss from operations widened to $7.0 million in 2025, compared to a loss of $2.3 million in 2024. Net loss for 2025 was $7.97 million, compared to a net loss of $2.29 million in 2024. Cash and cash equivalents as of December 31, 2025, were $2.1 million, slightly up from $2.09 million in 2024. The company is actively pursuing growth initiatives in pharmaceutical logistics, specialty distribution, and U.S. onshoring. Key business highlights include new partnerships with Attune Biotech and Revival Health, expansion into India, and strengthening emergency preparedness contracts.